Drug Research
Novo Nordisk invests DKK 850 million in production facilities in Kalundborg
Novo Nordisk announced plans to invest DKK 850 million in expanding its production facilities in Kalundborg, Denmark. This new investment brings Novo Nordisk’s total investments in site Kalundborg to more than DKK 2 billion in 2020. Novo Nordisk currently...
Drug Research
Indian government starts talks to procure COVID-19 vaccine
Covid-19 vaccines being developed by UK’s Oxford-AstraZeneca and United States’s Moderna-NIAID are the top candidates India is looking at for possible acquisition discussions, senior government officials aware of the country’s vaccine strategy said, adding that a group of experts...
Drug Research
Therapure Biomanufacturing Signs Manufacturing Deal With VBI Vaccines for Coronavirus Vaccine Candidates
Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates. Therapure Biomanufacturing is an integrated contract development and manufacturing organization (CDMO) focused...
Drug Research
Memo Therapeutics and Northway Biotech collaborate on the fast-track manufacturing of a SARS-CoV-2-neutralizing antibody for the therapy of COVID-19
Swiss biotech company Memo Therapeutics AG (MTx), and Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announce a new partnership to manufacture MTx’s therapeutic COVID-19 antibody candidate in a 4 month fast-track process approved by...
Drug Research
Caprion-HistoGeneX, Viroclinics-DDL Announce COVID-19 Research Partnership
Caprion-HistoGeneX and Viroclinics-DDL announced a new strategic partnership to expand their global capabilities addressing the emerging needs for therapeutic and prophylactic solutions to target infectious diseases including COVID-19. This partnership brings together the leadership of two contract research organizations...
Drug Research
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Daiichi Sankyo Company, Limited announced that it has entered into a global development and commercialization agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), currently in phase 1 clinical development for non-small cell...
Drug Research
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
Editas Medicine, Inc., a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that they have entered into...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.